Calithera Biosciences, Inc. CALA
OTC PK
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -- | -- |
| Cost of Revenue | -46.62% | -33.95% | -- | -- | -- |
| Gross Profit | 34.71% | 20.26% | -- | -- | -- |
| SG&A Expenses | -35.06% | -28.81% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.39% | 32.17% | -- | -- | -- |
| Operating Income | 63.55% | -50.88% | -- | -- | -- |
| Income Before Tax | 65.55% | -48.92% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.55% | -48.92% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.55% | -48.92% | -- | -- | -- |
| EBIT | 63.55% | -50.88% | -- | -- | -- |
| EBITDA | 63.68% | -51.16% | -- | -- | -- |
| EPS Basic | 83.91% | -16.34% | -- | -- | -- |
| Normalized Basic EPS | 71.60% | -35.93% | -- | -- | -- |
| EPS Diluted | 73.51% | -33.37% | -- | -- | -- |
| Normalized Diluted EPS | 72.48% | -34.49% | -- | -- | -- |
| Average Basic Shares Outstanding | 25.41% | 19.64% | -- | -- | -- |
| Average Diluted Shares Outstanding | 31.07% | 25.38% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |